Omipalisib - CAS 1086062-66-9
Catalog number: 1086062-66-9
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C25H17F2N5O3S
Molecular Weight:
505.5
COA:
Inquire
Targets:
mTOR
Description:
Omipalisib, also known as GSK2126458, is asmall-molecule pyridylsulfonamide inhibitor of phosphatidylinositol 3-kinase (PI3K) with potential antineoplastic activity. PI3K inhibitor GSK2126458 binds to and inhibits PI3K in the PI3K/mTOR signaling pathway, which may trigger the translocation of cytosolic Bax to the mitochondrial outer membrane, increasing mitochondrial membrane permeability and inducing apoptotic cell death. Bax is a member of the proapoptotic Bcl2 family of proteins. PI3K, often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.
Appearance:
light yellow solid powder
Synonyms:
GSK-2126458; GSK2126458; GSK 2126458; Omipalisib
MSDS:
Inquire
InChIKey:
CGBJSGAELGCMKE-UHFFFAOYSA-N
InChI:
InChI=1S/C25H17F2N5O3S/c1-35-25-23(32-36(33,34)24-5-3-18(26)12-21(24)27)11-17(13-29-25)15-2-4-22-20(10-15)19(7-8-28-22)16-6-9-30-31-14-16/h2-14,32H,1H3
Canonical SMILES:
COC1=C(C=C(C=N1)C2=CC3=C(C=CN=C3C=C2)C4=CN=NC=C4)NS(=O)(=O)C5=C(C=C(C=C5)F)F
Current Developer:
GSK
1.Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.
Villanueva J;Infante JR;Krepler C;Reyes-Uribe P;Samanta M;Chen HY;Li B;Swoboda RK;Wilson M;Vultur A;Fukunaba-Kalabis M;Wubbenhorst B;Chen TY;Liu Q;Sproesser K;DeMarini DJ;Gilmer TM;Martin AM;Marmorstein R;Schultz DC;Speicher DW;Karakousis GC;Xu W;Amaravadi RK;Xu X;Schuchter LM;Herlyn M;Nathanson KL Cell Rep. 2013 Sep 26;4(6):1090-9. doi: 10.1016/j.celrep.2013.08.023. Epub 2013 Sep 19.
Although BRAF and MEK inhibitors have proven clinical benefits in melanoma, most patients develop resistance. We report a de novo MEK2-Q60P mutation and BRAF gain in a melanoma from a patient who progressed on the MEK inhibitor trametinib and did not respond to the BRAF inhibitor dabrafenib. We also identified the same MEK2-Q60P mutation along with BRAF amplification in a xenograft tumor derived from a second melanoma patient resistant to the combination of dabrafenib and trametinib. Melanoma cells chronically exposed to trametinib acquired concurrent MEK2-Q60P mutation and BRAF-V600E amplification, which conferred resistance to MEK and BRAF inhibitors. The resistant cells had sustained MAPK activation and persistent phosphorylation of S6K. A triple combination of dabrafenib, trametinib, and the PI3K/mTOR inhibitor GSK2126458 led to sustained tumor growth inhibition. Hence, concurrent genetic events that sustain MAPK signaling can underlie resistance to both BRAF and MEK inhibitors, requiring novel therapeutic strategies to overcome it.
2.AACR-NCI-EORTC--21st International Symposium. Molecular targets and cancer therapeutics--Part 2.
Walker K;Padhiar M IDrugs. 2010 Jan;13(1):10-2.
The 21st international symposium of the American Association for Cancer Research (AACR), the NCI and the European Organization for Research and Treatment of Cancer (EORTC), held in Boston, included topics covering the development of therapeutics and molecular targets in the field of cancer research. This conference report highlights selected presentations on the development of novel drugs for cancer. Investigational drugs discussed include RO-506876 (F Hoffmann-La Roche Ltd), GDC-0980 (Genentech Inc), EMD-1214063 and EMD-1204831 (Merck Serono SA), AR-mTOR01 and AR-mTOR-26 (Array BioPharma Inc), GSK-2126458 (GlaxoSmithKline plc), EXEL-1415 and EXEL-2008 (Exelixis Inc), FP-1039 (FivePrime Therapeutics Inc), and AV-412 (AVEO Pharmaceuticals Inc).
3.Nevospheres from neurocutaneous melanocytosis cells show reduced viability when treated with specific inhibitors of NRAS signaling pathway.
Basu D;Salgado CM;Bauer BS;Johnson D;Rundell V;Nikiforova M;Khakoo Y;Gunwaldt LJ;Panigrahy A;Reyes-Múgica M Neuro Oncol. 2016 Apr;18(4):528-37. doi: 10.1093/neuonc/nov184. Epub 2015 Sep 9.
BACKGROUND: ;Neurocutaneous melanocytosis (NCM) is characterized by clonal nevomelanocytic proliferations in the CNS and skin. Given the scarcity of effective therapeutic targets, testing new drugs requires a reliable and reproducible in vitro cellular model of the disease.;METHODS: ;We generated nevomelanocytic spheroids in vitro from lesions of the spinal cord, brain, and skin from 4 NCM patients. Nevomelanocytic cells were grown as monolayers or spheroids and their growth characteristics were evaluated. Cultured cell identity was confirmed by demonstration of the same NRAS mutation found in the original lesions and by immunophenotyping. Nevomelanocytic spheroids were treated with inhibitors of specific mediators of the NRAS signaling pathway (vemurafenib, MEK162, GDC0941, and GSK2126458). Drug sensitivity and cell viability were assessed.;RESULTS: ;Cultured cells were growth-factor dependent, grew as spheroids on Geltrex matrix, and maintained their clonogenicity in vitro over passages. Skin-derived cells formed more colonies than CNS-derived cells. Inhibitors of specific mediators of the NRAS signaling pathway reduced viability of NRAS mutated cells. The highest effect was obtained with GSK2126458, showing a viability reduction below 50%.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related mTOR Products


CAS 1086062-66-9 Omipalisib

Omipalisib
(CAS: 1086062-66-9)

Omipalisib, also known as GSK2126458, is asmall-molecule pyridylsulfonamide inhibitor of phosphatidylinositol 3-kinase (PI3K) with potential antineoplastic acti...

CAS 1676893-24-5 NSC781406

NSC781406
(CAS: 1676893-24-5)

NSC781406 demonstrates potent PI3K inhibition (PI3Kα IC50=2.0 nM) and is a highly potent mTOR inhibitor, with reasonable liver microsome stability.

CAS 1092788-83-4 PP121

PP121
(CAS: 1092788-83-4)

PP121 is a multitargeted dual receptor tyrosine kinases inhibitor. PP121 blocks the proliferation of tumor cells by direct inhibition of oncogenic tyrosine kin...

SC-III3
(CAS: 1660110-65-5)

SC-III3 is a scopoletin derivative and has been found to induce the autophagy of hepatoma HepG2 cells so that could be significant in anticancer studies.

CAS 1429639-50-8 CZ415

CZ415
(CAS: 1429639-50-8)

CZ415 is a highly selective potent mTOR inhibitor with little activity on other lipid and protein kinases with efficacy in a collagen induced arthritis model an...

CAS 53123-88-9 Rapamycin

Rapamycin
(CAS: 53123-88-9)

Rapamycin is a mTOR inhibitor immunosuppressant and kinase inhibitor with both antifungal and antineoplastic properties. It selectively inhibits the transcripti...

CAS 915019-65-7 Dactolisib

Dactolisib
(CAS: 915019-65-7)

Dactolisib, also known as BEZ235, is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. BEZ235 speci...

CAS 1251156-08-7 XL388

XL388
(CAS: 1251156-08-7)

XL388 is a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR). XL388 inhib...

CAS 1033735-94-2 GNE-493

GNE-493
(CAS: 1033735-94-2)

GNE-493 is a potent, selective, and orally available dual pan-PI3K/mTOR inhibitor with IC50s of 3.4/12/16/16/32 nM for PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ/mTOR respectively...

CAS 1028385-32-1 BEZ235 Tosylate

BEZ235 Tosylate
(CAS: 1028385-32-1)

BEZ235 tosylate is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assay...

CC-115
(CAS: 1228013-15-7)

CC-115, a DNA-PK and mTOR inhibitor, has been found to have probable anticarcinoma effect. IC50:13 nM and 21 nM for DNA-PK and mTOR respectively.

CAS 1032754-81-6 GNE-477

GNE-477
(CAS: 1032754-81-6)

GNE-477 is a potent and efficacious dual PI3K/mTOR inhibitor with IC50 of 4 nM for PI3Kα and Kiapp of 21 nM for mTOR.

CAS 1013098-90-2 PI3Kα/mTOR-IN-1

PI3Kα/mTOR-IN-1
(CAS: 1013098-90-2)

PI3Kα/mTOR-IN-1 is a potent dual inhibitor of PI3Kα/mTOR (Kis= 10.6 nM and 12.5 nM for mTOR and PI3Kα, respectively).

CAS 1223001-51-1 Torin 2

Torin 2
(CAS: 1223001-51-1)

Torin 2 inhibits ATM/ATR/DNA-PK with EC50 of 28 nM/35 nM/118 nM, in PC3 cell lines respectively. It is potentially used as an antineoplastic agent.

CAS 572924-54-0 Ridaforolimus

Ridaforolimus
(CAS: 572924-54-0)

Ridaforolimus is a small molecule and non-prodrug analogue of the lipophilic macrolide antibiotic rapamycin with potential antitumor activity. Ridaforolimus bin...

CAS 1207358-59-5 mTOR-IN-1

mTOR-IN-1
(CAS: 1207358-59-5)

Selective inhibitors of mammalian target of rapamycin (mTOR) kinase based upon saturated heterocycles fused to a pyrimidine core were designed and synthesized. ...

CAS 958852-01-2 GSK1059615

GSK1059615
(CAS: 958852-01-2)

GSK1059615 is a dual inhibitor of PI3Kα/β/δ/γ (reversible) and mTOR with IC50 of 0.4 nM/0.6 nM/2 nM/5 nM and 12 nM, respectively.

CAS 934529-30-3 XL PI3K/mTOR inhibitor

XL PI3K/mTOR inhibitor
(CAS: 934529-30-3)

An orally bioactive PI3K/mTOR tyrosine kinase inhibitor.

CAS 1207360-89-1 GDC-0349

GDC-0349
(CAS: 1207360-89-1)

GDC-0349 is a small molecule anticaner drug candidate, being developed by Genentech. As of July 2012, Genentech has filed phase I trial of GDC-0349 for evaluati...

CAS 6724-53-4 Perhexiline maleate salt

Perhexiline maleate salt
(CAS: 6724-53-4)

Perhexiline maleate salt is a carnitine palmitoyltransferase 1 (CPT1) and CPT2 inhibitor. It is an anti-anginal metabolic modulator and used in treatments for a...

Chemical Structure

CAS 1086062-66-9 Omipalisib

Quick Inquiry

Verification code

Featured Items